2 Fast-Growing Pharmaceutical Stocks to Buy Now
The Motley Fool highlights Incyte (INCY) and TG Therapeutics (TGTX) as growth biotech stocks. For Incyte, it cites Q1 Jakafi sales of $758M (+7% YoY), Opzelura sales of $143M (+20%), revenue of $1.27B (+21%), and adjusted EPS $1.81 vs $1.34 consensus, plus a $1.25B Vega Therapeutics acquisition. For TG, it notes Briumvi U.S. sales of $194.8M in Q1 and raised full-year revenue guidance to $925M.
How this was made
The 30-second read
Why it matters
For INCY, the cited Q1 sales and adjusted EPS beat, plus a $1.25B acquisition and stated phase 3/approval cadence, can influence near-term valuation expectations. For TGTX, raised full-year revenue guidance tied to Briumvi U.S. sales is a more direct earnings trajectory catalyst.
Market read
This is primarily an editorial “buy” article, but it includes concrete Q1 financial datapoints for INCY and raised guidance for TGTX that can affect short-term positioning.
What to watch
Key risks like payer pressure, competitive dynamics in MS/dermatology, trial readouts for late-stage assets, and integration/clinical execution after acquisitions are not quantified here.
Background
The article profiles Incyte’s JAK inhibitor and dermatology franchise and TG Therapeutics’ Briumvi-driven growth, citing Q1 sales and guidance changes plus pipeline commentary.
Ticker impact
Incyte reported Q1 Jakafi sales of $758M (+7% YoY) and Opzelura sales of $143M (+20% YoY), with adjusted EPS $1.81 beating consensus.
Moderately positive bias for the next few sessions as traders digest the cited Q1 beats and pipeline/approval cadence.
This is a promotional buy article, but it includes concrete financial figures and a $1.25B acquisition plus management’s phase 3 and approval expectations, which can move valuation assumptions.
TG Therapeutics raised full-year revenue guidance to $925M after Briumvi generated $194.8M in Q1 U.S. sales, and raised Briumi guidance to $885M-$900M.
Positive near-term bias, especially for momentum traders, as raised guidance is a direct catalyst.
The article cites specific guidance and sales numbers, but it is still an editorial framing rather than a primary filing or earnings release transcript.
Market effects
Reinforces the market narrative that commercial-stage biotech with differentiated franchises can sustain growth via pipeline diversification and guidance momentum.
Primarily US biotech sentiment; limited direct regional spillover beyond US-listed peers.
Could marginally support global MS and hematology/dermatology pharma sentiment, but no cross-border deal or regulator action is disclosed.
Counterpoint
The piece is a “buy now” template and may overemphasize narrative catalysts; without new primary disclosures (e.g., the actual earnings release or filing), the incremental trading edge may be limited.
Key entities
- companyIncyte
Commercial-stage biotech; cited Q1 Jakafi and Opzelura sales, adjusted EPS beat, and a $1.25B Vega Therapeutics acquisition.
- companyTG Therapeutics
Commercial-stage biotech; cited Briumvi momentum and raised full-year revenue guidance.
